Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
Conditions
Colorectal Cancer · Colorectal Adenocarcinoma · Rectal Adenocarcinoma · Rectal Cancer, Adenocarcinoma · Rectal Cancer, Metastatic · Colon Cancer Metastatic · Colon Cancer Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Hopital Prive Jean Mermoz, Lyon, France
Contact: Study coordinator (Pascal Artru, MD)Hôpital La Timone - APHM, Marseille, France
Contact: Study coordinator (Laétitia Dahan, Prof)Hopital Saint Louis, Paris, France
Contact: Study coordinator (Thomas Aparicio, Prof)Centre Hospitalier Universitaire Reims, Reims, France
Contact: Study coordinator (Olivier Bouché, Prof)Groupe Hospitalier Rance Emeraude, St-Malo, France
Contact: Study coordinator (Juliette Viaud, MD)Charite Universitaetsmedizin, Berlin, Germany
Contact: Study coordinator (Dominik P Modest, Prof)Krankenhaus Nordwest, Frankfurt, Germany
Contact: Study coordinator (Thorsten Götze, MD)Istituto Tumori Bari Giovanni Paolo II, Bari, Bari, Italy
A.O.U Careggi, Florence, Firenze, Italy
Contact: Study coordinator (Lorenzo Antonuozzo)Istituto Europeo Di Oncologia S.r.l., Milan, Italy, Italy
Azienda Unita Sanitaria Locale Della Romagna, Ravenna, Italy, Italy
Humanitas Mirasole S.p.A., Rozzano, Italy, Italy
Contact: Study coordinator (Alberto Puccini, MD) · alberto.puccini@cancercenter.humanitas.it · +390282247255Azienda Ospedaliera Card. G. Panico, Tricase, LE, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori - Milano, Milan, Milan, Italy
Contact: Study coordinator (Alessandra Raimondi, MD) · alessandra.raimondi@istitutotumori.mi.it · 0039-0223803835Azienda Ospedaliero Universitaria di Modena, Modena, Missouri, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, RM, Italy
Policlinico Tor Vergata Roma, Roma, Roma, Italy
Contact: Study coordinator (Vincenzo Formica)IFO-Regina Elena Institute for Cancer Research, Roma, Roma, Italy
Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy
Contact: Study coordinator (Maria Elena Casagrande)Azienda Ospedaliera Universitaria Luigi Vanvitelli, Naples, Italy
IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale", Naples, Italy
Contact: Study coordinator (Antonio Avallone, MD)Fondazione IRCCS Istituto Oncologico Veneto, Padova, Italy
Contact: Study coordinator (Sara Lonardi, MD)U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy
Hospital del Mar, Barcelona, Spain
Contact: Study coordinator (Clara Montagut Viladot, MD)Hospital Universitario Virgen de las Nieves, Granada, Spain
Contact: Study coordinator (Encarnación González Flores, MD)Hospital Universitario Fundación Jiménez, Madrid, Spain
Contact: Study coordinator (Raquel Fuentes Mateos, MD)Hospital Clínico Universitario Santiago de Compostela, Santiago de Compostela, Spain
Contact: Study coordinator (Sonia Candamio Folgar, MD)Hospital Clínico Universitario de Valencia, Valencia, Spain
Contact: Study coordinator (Susana Roselló Keranen, MD)
Study leads
Filippo Pietrantonio, MD
Principal Investigator
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano